3Strain WD. The use of recombinant human B - type natriuretic peptide (nesiritide) in the management of acute decompensated heart failure[J]. Int J Clin Pract, 2004,58(11) : 1081 - 1087.
5Gegenhuber A, Mueller T, Firlinger F, et al. Timer course of B-type natriuretic peptide (BNP) and N - terminal pro - BNP changes in patients with decompensated heart failure[J]. Clin Chem, 2004,50:454 - 456.
7Karl S, John C, Wlson S, et al. Guidelines for the diagnosisand treatment of chronic heart failure: executive summary[J]. Euro - pean Heart Journal,2005,26(6) :1115 - 1140.
二级参考文献59
1[4]McCullough PA, Omland T, Maisel AS. B-type natriuretic peptides: a diagnostic breakthrough for clinicians[J]. Rev Cardiovasc Med, 2003,4(2):72-80.
2[5]Minna AK, Jarkko M, Keijo P, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-Type Natriuretic Peptides [J]. Clin Chem, 2004,50(9):1576-1588.
3[6]Qi W, Mathisen P, Kjekshus J, et al. Natriuretic peptides in patients with aortic stenosis[J]. Am Heart J, 2001, 142(4): 725-732.
4[7]Hans K, Mery B, Hans K, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device[J]. Clin Chem, 2004,50(9):1670-1672.
5[8]Rademaker MT, Charles C J, Espiner EA, et al. Combined inhibition of angiotensin Ⅱ and endothelin suppresses the brain natriuretic peptide response to developing heart failure[J]. Clin Sci (Lond), 2004, 106(6):569-576.
6[9]Kapoun AM, Faquan L, O′Young G, et al. Functional opposition to transforming growth factor-β in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion, proliferation, and inflammation[J]. Circ Res,2004, 94(4):453-461.
7[10]Gegenhuber A, Mueller T, Firlinger F, et al. Time course of B-type natriuretic peptide(BNP) and N-terminal proBNP changes in patients with decompensated heart failure[J]. Clin Chem, 2004,50(2):454-456.
8[11]Troughton RW, Prior DL, Pereira JJ, et al. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function[J]. J Amer Coll Cardiol, 2004,43(3) :416-422.
10[13]Alan HB, Andrew S, Stacey W, et al. Biological variation for N-terminal pro- and B-type natriuretic peptides and implications for therapeutic monitoring of patients with congestive heart failure[J]. Am J Cardiol, 2003,92(5):628-631.
